Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Monthly VGA039 May Improve Daily Life for Patients Living With von Willebrand Disease
6+ hour, 28+ min ago (619+ words) A once-monthly experimental treatment for von Willebrand disease may do more than reduce bleeding episodes—it could also help patients regain confidence, participate more fully in work and school, and enjoy activities they previously avoided, according to a new qualitative…...
Five-Year Data Support Neoadjuvant THP in ERBB2-Positive Breast Cancer
3+ day, 11+ hour ago (279+ words) The neoadjuvant combination of paclitaxel, trastuzumab, and pertuzumab (THP) shows promise for treating early-stage ERBB2-positive breast cancer. However, evidence on THP’s long-term outcomes is limited, and the role of ultrasensitive circulating tumor DNA (ctDNA) monitoring remains uncertain. In a prespecified…...
What’s Missing from OPTIMA? Key Limitations Every Clinician Should Know
1+ mon, 3+ week ago (78+ words) What are the key limitations, such as follow-up duration or undisclosed ROR scores, of the OPTIMA trial that clinicians should keep in mind before broadly implementing test-directed chemotherapy decisions? Stein RC, et al. 2026 American Society of Clinical Oncology Annual Meeting....
Does Tumor Biology Matter More Than Node Status in Breast Cancer?
1+ mon, 3+ week ago (119+ words) Docwire News Does Tumor Biology Matter More Than Node Status in Breast Cancer? Abirami Sivapiragasam, MD, explains how OPTIMA trial findings contribute to the ongoing debate between tumor biology and anatomical staging in guiding chemotherapy decisions for early breast cancer....
Risk Profiling in Early HR+ Breast Cancer: How Genomics Is Changing Care
1+ mon, 3+ week ago (191+ words) Watch the other segments here: Oral SERDs on the Rise: What lidERA and SERENA‑6 Mean for Early HR+ Care How Do You Select the Right Therapy in Personalized HR+ Breast Cancer Care? The Role of ctDNA in HR+ Breast Cancer:…...
Giredestrant Shows Consistent IDFS Benefit Regardless of Menopausal Status in Early Breast Cancer
1+ mon, 3+ week ago (333+ words) Giredestrant demonstrates invasive disease-free survival (IDFS) benefit regardless of menopausal status among patients with estrogen receptor-positive/HER2-negative (ER+/HER2-) early breast cancer (eBC), according to findings from the phase 3 lidERA BC trial to be presented at the 2026 American Society of Clinical…...
OPTIMA Phase III: Gene Expression Test Helps Identify Patients Who May Avoid Chemotherapy
1+ mon, 3+ week ago (226+ words) The non-inferiority (NI) randomized controlled OPTIMA trial (Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis) evaluated whether a Prosigna gene expression test-directed approach could maintain comparable 5-year invasive breast cancer-free survival (IBCFS) outcomes relative to standard treatment. Results…...
Expert Exchange: ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer
2+ mon, 1+ week ago (171+ words) Docwire News Expert Exchange: ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer Expert Roundtable: Managing ESR1‑Mutated ER+/HER2– Metastatic Breast Cancer This five‑episode expert roundtable brings together leading breast oncologists for a candid, practice‑focused discussion on managing ESR1‑mutated ER‑positive/HER2‑negative…...
SATEEN: Limited Activity With Sacituzumab Govitecan Plus Trastuzumab After Prior T-DXd in
2+ mon, 2+ week ago (248+ words) Results from the phase II SATEEN trial presented this week at the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany, suggest that sacituzumab govitecan (SG) plus trastuzumab has limited activity in patients with HER2-positive metastatic…...
Can Dynamic Biomarkers Change Treatment Decisions?
3+ mon, 2+ week ago (476+ words) Docwire News Can Dynamic Biomarkers Change Treatment Decisions? Margaret Gatti‑Mays, MD, MPH, examines whether dynamic biomarkers such as circulating tumor DNA (ctDNA) are ready to meaningfully change treatment decisions in breast cancer care. She outlines key practical challenges clinicians…...